Pulmonary hypertension secondary to lung diseases, as chronic obstructive pulmonary disease (COPD) and idiopathic pulmonary fibrosis (IPF), is a relatively common condition with a bad prognosis. During the last World Congress in Nizza, detailed instructions about pulmonary hypertension secondary to lung diseases were provided. Long-term oxygen therapy is not able to normalize pulmonary artery pressure (PAP) values or to counteract vascular remodeling; the use of specific drug for pulmonary hypertension secondary to COPD or IPF, especially in severe forms, has often been suggested, but full indications have not yet been supplied.
pertensione polmonare in corso di malattie parenchimali polmonari: Quali prospettive terapeutiche? / D. Elia, R. Cassandro, S. Harari. - In: RASSEGNA DI PATOLOGIA DELL’APPARATO RESPIRATORIO. - ISSN 0033-9563. - 31:3(2016), pp. 131-136.
pertensione polmonare in corso di malattie parenchimali polmonari: Quali prospettive terapeutiche?
S. Harari
2016
Abstract
Pulmonary hypertension secondary to lung diseases, as chronic obstructive pulmonary disease (COPD) and idiopathic pulmonary fibrosis (IPF), is a relatively common condition with a bad prognosis. During the last World Congress in Nizza, detailed instructions about pulmonary hypertension secondary to lung diseases were provided. Long-term oxygen therapy is not able to normalize pulmonary artery pressure (PAP) values or to counteract vascular remodeling; the use of specific drug for pulmonary hypertension secondary to COPD or IPF, especially in severe forms, has often been suggested, but full indications have not yet been supplied.Pubblicazioni consigliate
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.